Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GlaxoSmithKline

- PMLiVE

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

The vaccine has been approved to use in those aged 12 months and above

- PMLiVE

Rare cancer specialists Sierra Oncology acquired by GSK for £1.5bn

Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis

- PMLiVE

GSK and CureVac sign deal with Germany for mRNA COVID-19 vaccines

The agreement is part of a Pandemic Preparedness Contract and means millions of vaccines can be produced at short notice during future public health emergencies

dengue fever mosquito

WHO has recommended GSK’s malaria vaccine for children

This is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children

- PMLiVE

CureVac to push ahead with first- and second-generation COVID-19 vaccines

The biotech will seek EMA approval for first-generation jab while trials are due to start for second-generation jabs in Q4

- PMLiVE

GSK beats expectations thanks to strong vaccine sales in Q2

GSK's vaccine business was up by 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

GSK reveals plans for £400m R&D facility expansion in England

GSK has formally started the process of seeking a development partner for the expansion plans

- PMLiVE

GSK supports CEO Emma Walmsley following Elliott’s demands for leadership overhaul

GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business

- PMLiVE

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

The focus of the deal is two clinical-stage monoclonal antibodies in development for a number of neurodegenerative diseases

- PMLiVE

Elliott Management puts pressure on GSK after years of ‘disappointing performance’

Hedge fund has published a 17-page letter outlining recommendations following GSK's investor day last week

- PMLiVE

Final data shows CureVac’s COVID-19 vaccine is only 48% effective

New data shows slight improvement over previously reported 47% overall efficacy in interim analysis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links